Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo.
Investigations into tumor angiogenesis and antiangiogenic treatment have renewed interest in tumor perfusion. To image tumor blood-pool by PET, suitable tracers are not generally available. In this experimental study, we characterized a 68Ga-labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) conjugate of rat serum albumin (68Ga-DOTA-RSA) in vivo using a generator-produced isotope. Biodistribution was determined in ACI rats after intravenous administration of 3-6 MBq of 68Ga-DOTA-RSA. Three ACI rats were imaged over 1 h by dynamic PET after intravenous administration of 15-25 MBq of 68Ga-DOTA-RSA while the blood-pool activity was recorded simultaneously in a closed extracorporeal loop (ECL) between the carotid artery and the jugular vein. Time-activity curves (TACs) were obtained from volume of interest (VOI) analysis and from the ECL data. Stability and metabolites in plasma and urine were analyzed by size exclusion HPLC (SE-HPLC) 1 h after intravenous injection of 67Ga-DOTA-RSA. Blood radioactivity decreased by 10% and 18% from 10 to 60 min p.i. by biodistribution and PET or ECL, respectively. Tissue sampling between 10 and 60 min p.i. showed slight increases in the uptake of spleen, myocardium, kidney and skeletal muscle while hepatic accretion remained unchanged. Total urinary excretion after 60 min amounted to 9% of the injected dose. HPLC demonstrated a single urinary metabolite corresponding in size to gallium-labeled DOTA. 68Ga-DOTA-RSA is a blood-pool tracer whose physical and biological half-life is well suited for PET. Our findings support clinical imaging using 68Ga-DOTA-labeled human serum albumin (HSA). The generator-produced label makes 68Ga-DOTA-labeled albumin continuously available even to centers lacking an in-house cyclotron.
Hoffend
Johannes
J
Division of Nuclear Medicine, Department of Radiology, University of Heidelberg, 69120 Heidelberg, Germany. johannes_hoffend@med.uni-heidelberg.de
Mier
Walter
W
Schuhmacher
Jochen
J
Schmidt
Kerstin
K
Dimitrakopoulou-Strauss
Antonia
A
Strauss
Ludwig G
LG
Eisenhut
Michael
M
Kinscherf
Ralf
R
Haberkorn
Uwe
U
D000818:Animals; D001372:Aza Compounds / Q000493:pharmacokinetics*; D001783:Blood Flow Velocity; D006528:Carcinoma, Hepatocellular / Q000098:blood supply* / Q000000981:diagnostic imaging* / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D005710:Gallium Radioisotopes / Q000493:pharmacokinetics*; D015637:Gated Blood-Pool Imaging / Q000379:methods*; D008657:Metabolic Clearance Rate; D009928:Organ Specificity; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D051381:Rats; D011912:Rats, Inbred ACI; D012709:Serum Albumin / Q000493:pharmacokinetics*; D014018:Tissue Distribution
D001372:Aza Compounds; D005710:Gallium Radioisotopes; D019275:Radiopharmaceuticals; D012709:Serum Albumin